-
Media Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media Release
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media Release
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media Release
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media Release
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
-
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval